Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced a summary of its actions to improve its capital position, including the recently announced private repurchases…
The FDA accepted Cidara Therapeutics Inc’s (NASDAQ:CDTX) marketing application seeking approval for rezafungin for candidemia and invasive candidiasis. Under the priority…
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19 infection.
The European Commission approved AstraZeneca Plc’s (NASDAQ:AZN) Tezspire (tezepelumab) as an add-on maintenance treatment for severe asthma. The approval covers patients…
Press release – No. 6 / 2022
Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)
BI 456906
FLORHAM PARK, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and
First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post infusion
Sleeping Beauty TCR-T cell therapy had a manageable safety
Treatment with CNM-Au8 significantly improved long-term survival with approximately a 70% decreased risk of mortality vs. original placebo randomization
Comparable survival benefits were also